IgG4-related kidney disease: treatment standard. (PubMed, Nephrol Dial Transplant) - Oct 10, 2026 - "Conventional immunosuppressive agents have been used with controversial results, whereas B-cell-targeting therapies, particularly rituximab, have demonstrated high efficacy in both induction and maintenance settings...Long-term monitoring is essential because of the relapsing nature of the disease and the potential for chronic kidney disease. This Treatment Standard provides a practical, nephrology-oriented framework for the diagnosis, treatment and follow-up of IgG4-related kidney disease, integrating current evidence with emerging insights from immunopathogenesis and clinical trials."
Journal • Chronic Kidney Disease • Fibrosis • Glomerulonephritis • Immunology • Inflammation • Nephrology • Renal Disease
|
|
Augusto Vaglio; Francesco Peyronel; Giulia Palazzini; Lorenzo Masieri; Riccardo Campi; Salvatore Granata
|